Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma

NCT02367651 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study cancelled: Withdrawn before enrollment of any participants

Conditions

Sarcoma, Soft Tissue

Interventions

DRUG: Pazopanib 800 mg
DRUG: Placebo

Sponsor

GlaxoSmithKline